TCR Cure
Nansha
About TCR Cure
TCR Cure provides R&D and industrialization of tumor immune cell therapy technology with engineered T cells as the ultimate target. With the development of a series of CAR-T, TCR-T, CAR-NK, and TIL immune cell therapy products, the cure rate of tumors is improved, and the mortality rate, recurrence rate, and disability rate of tumors are reduced. TCR Cure is on a mission to conquer cancer and is dedicated to assisting patients and doctors in slowing and eventually curing tumors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $52.9M
- Funding stage: Late Stage Venture
- Last round: Series C (Jul 2021)
- Website: tcrcure.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/tcr-cure-19897 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.